United Neuroscience

United Neuroscience, now known as @vaxxinity, is a clinical stage biotech company founded in 2014 with its headquarters in Ireland. They are dedicated to developing cutting-edge therapies for the brain, particularly focusing on Alzheimer's and other neurological disorders. The company is at the forefront of pioneering endobody vaccines, a new class of medicine, utilizing proprietary platform technologies that have commercially proven themselves with over 3 billion doses administered across multiple indications. The company's commitment to addressing seemingly insurmountable challenges is evident in their bold vision of halving the incidence of Alzheimer's by 2050 and eradicating neurodegenerative diseases prophylactically. This ambitious goal aligns with their determination to transform the lives of patients and families affected by Alzheimer’s, Parkinson’s, ALS, and other neurological diseases. United Neuroscience has successfully launched one of only a handful of licensed vaccines against an endogenous host protein in the world. They have also developed a robust translational platform to swiftly design and develop targeted immunotherapeutics, leveraging their industry-leading endobody vaccine technology. Despite not having disclosed their last investment details, the company's bold approach and potential to significantly impact the neurological treatment landscape make them a noteworthy player in the biotech industry.